Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
Journal: Journal for immunotherapy of cancer
Published: March 03, 2022
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Journal: Nature communications
Published: September 27, 2019
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Journal: JAMA oncology
Published: June 14, 2019
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Journal: JAMA oncology
Published: June 14, 2019
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: March 01, 2018
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
Journal: Blood cancer journal
Published: February 04, 2017
An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 24, 2016
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
Journal: Investigational new drugs
Published: February 17, 2016
Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium.
Journal: Leukemia & lymphoma
Published: December 18, 2015
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 07, 2015
Last Updated: 09/26/2026